GlobeNewswire: Wuhan General Group (China), Inc. Contains the last 10 of 29 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:46:01ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/11/07/1943336/0/en/Wuhan-to-Launch-CBD-Cosmetics-and-CBD-Infused-Coffee-in-South-Africa.html?f=22&fvtc=4&fvtv=44337Wuhan to Launch CBD Cosmetics and CBD Infused Coffee in South Africa2019-11-07T16:04:30Z<![CDATA[Montreal, Nov. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Wuhan General Group, Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), is pleased to announce the following corporate updates:]]>https://www.globenewswire.com/news-release/2019/08/15/1902501/0/en/Wuhan-General-Group-Appoints-Distinguished-Scientist-Dr-Hyder-A-Khoja-as-Chief-Scientific-Officer.html?f=22&fvtc=4&fvtv=44337Wuhan General Group Appoints Distinguished Scientist Dr. Hyder A. Khoja as Chief Scientific Officer2019-08-15T12:34:51Z<![CDATA[Barcelona, Spain, Aug. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Wuhan General Group, Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), is positioning itself to become a major player in the US$166B medical CBD (cannabidiol) space, as well as the promising psilocybin and medicinal mushroom health sector. The company is pleased to announce that Dr. Hyder A. Khoja (“Dr. Khoja”) is joining Wuhan General Group as Chief Scientific Officer. In his role as CSO, Dr. Khoja will oversee the company’s core research and product development to commercialization.]]>https://www.globenewswire.com/news-release/2019/08/07/1898549/0/en/Wuhan-Announces-Strategic-Reorganization-for-Its-Operational-Advancement-in-the-Medical-Marijuana-and-Psilocybin-Mushroom-Therapy-Markets.html?f=22&fvtc=4&fvtv=44337Wuhan Announces Strategic Reorganization for Its Operational Advancement in the Medical Marijuana and Psilocybin Mushroom Therapy Markets2019-08-07T16:12:12Z<![CDATA[BARCELONA, Spain, Aug. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Wuhan General Group, Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), is pleased to announce a strategic reorganization that will better position the company to capitalize on the rapidly changing Medical Marijuana and Psilocybin Mushroom industries, while more closely aligning the business with the company’s three primary growth strategies: optimizing the value of the core; increasing health and well-being product lines, and accelerating distribution of new business models.]]>https://www.globenewswire.com/news-release/2019/05/17/1827062/0/en/Wuhan-Expands-Capacity-to-Produce-Medicinal-Marijuana-and-Mushrooms.html?f=22&fvtc=4&fvtv=44337Wuhan Expands Capacity to Produce Medicinal Marijuana and Mushrooms2019-05-17T18:22:02Z<![CDATA[Wuhan General Group (China), Inc. Signs LOI to Acquire Significant Assets From Biodelta Nutraceuticals, Ltd. Wuhan General Group (China), Inc. Signs LOI to Acquire Significant Assets From Biodelta Nutraceuticals, Ltd.]]>https://www.globenewswire.com/news-release/2019/05/09/1821024/0/en/Psilocybin-Mushrooms-Decriminalized-in-Denver.html?f=22&fvtc=4&fvtv=44337Psilocybin Mushrooms Decriminalized in Denver 2019-05-09T16:10:22Z<![CDATA[Wuhan Provides Update on its Medicinal Mushrooms Division M2BIO Wuhan Provides Update on its Medicinal Mushrooms Division M2BIO]]>https://www.globenewswire.com/news-release/2019/04/05/1797796/0/en/Wuhan-Enters-Mushroom-Psychedelic-Medicine-Market.html?f=22&fvtc=4&fvtv=44337Wuhan Enters Mushroom Psychedelic Medicine Market2019-04-05T17:10:02Z<![CDATA[BARCELONA, Spain, April 05, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), announced today that its subsidiary MJ MedTech, Inc. (MJ MedTech) has created a new division dedicated to exploring opportunities in the psychedelic medicine space. The new division, M2BIO will be headed up by Wuhan's CMO, Dr. Anna Morera Lorelta.]]>https://www.globenewswire.com/news-release/2019/03/28/1781707/0/en/Wuhan-Updates-on-Hemp-and-CBD-Based-Products-Line.html?f=22&fvtc=4&fvtv=44337Wuhan Updates on Hemp and CBD-Based Products Line2019-03-28T19:41:33Z<![CDATA[BARCELONA, Spain, March 28, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Wuhan General Group (China), Inc. (OTC: WUHN) (the "Company" and "Wuhan"), announced today that its subsidiary MJ MedTech, Inc. (MJ MedTech) has commenced formulations and prototyping for the Dr. AnnaRx line of hemp and CBD based products.]]>https://www.globenewswire.com/news-release/2019/01/30/1707679/0/en/WUHAN-AND-BIODELTA-FORM-INTERNATIONAL-JOINT-VENTURE-To-launch-Dr-AnnaRx-CBD-Products-in-1-000-Pharmacies-Across-SA.html?f=22&fvtc=4&fvtv=44337WUHAN AND BIODELTA FORM INTERNATIONAL JOINT VENTURE - To launch Dr. AnnaRx CBD Products in 1,000 Pharmacies Across SA2019-01-30T14:02:24Z<![CDATA[LOS ANGELES, Jan. 30, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Wuhan General Group (China), Inc. (USOTC: WUHN) (the "Company" and "Wuhan"), announced today that its wholly-owned subsidiary MJ MedTech, Inc. (MJ MedTech) and Biodelta Nutraceuticals, Ltd. (Biodelta) have entered into a joint venture to develop, brand, market and commercialize the internationally trademarked Dr. AnnaRx.]]>https://www.globenewswire.com/news-release/2019/01/22/1703649/0/en/Wuhan-General-Group-acquires-MJ-MedTech.html?f=22&fvtc=4&fvtv=44337Wuhan General Group acquires MJ MedTech2019-01-22T16:04:53Z<![CDATA[MONTREAL, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), announces today that the Company has successfully completed the acquisition of MJ MedTech, a nutraceutical biotechnology company that owns, develops and commercializes a range of CBD-based products under the International trademarked brand Dr. AnnaRx.]]>https://www.globenewswire.com/news-release/2018/12/19/1669709/0/en/Wuhan-Provides-Update-on-Its-Entry-into-The-Cannabis-Market.html?f=22&fvtc=4&fvtv=44337Wuhan Provides Update on Its Entry into The Cannabis Market2018-12-19T16:00:12Z<![CDATA[MONTREAL, Dec. 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Wuhan General Group (China), Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), announces today that the Company is successfully gaining a strong foothold in Canada, Europe, US and Australia through Cannabis regulatory compliance, either by obtaining or having access to the needed permits to cultivate, transform and sell cannabis products in the permitted location.]]>